13F reference period
Q2 2026
Security Snapshot
Medicus Pharma Ltd. - Common shares, no par value (MDCX) Institutional Ownership
CUSIP: 58471K202
13F Institutional Holders and Ownership History from Q4 2024 to Q3 2026
Institutions Reporting
21
Shares (Excl. Options)
2.62M
Full value: 2,620,743 · shares · 30 Jun 2026Price
$0.45
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common shares, no par value
- Symbol
- MDCX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,620,743
- Total 13F value
- $1,179,646
- Portfolio coverage rank
- 0%
- Share change
- +301,262
- Value change
- +$129,618
- Number of holders
- 21
- Shares outstanding
- 91,685,830
- SEC-reported price per share
- $0.10
- Insider filing price
- $0.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- MDCX - Medicus Pharma Ltd. - Common shares, no par value is tracked under CUSIP 58471K202.
- 21 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 20 to 21 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$6.48M
Full value: $6,483,722 · USD · 31 Mar 2026.$1.18M
Full value: $1,179,646 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 21 institutions filings for Q2 2026.
Security key
58471K202
13F reference period
Q2 2026
13F holders
21
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
MDCX full holder history
Medicus Pharma Ltd. SEC filings
Medicus Pharma Ltd. company facts
Medicus Pharma Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 58471K202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
MDCX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Bokhari Raza | 5.3% | +10% | $1,700,772 | +$1,274,412 | 4,859,349 | +299% | BOKHARI, RAZA | 04 Sep 2026 |
| Melani Kenneth R. | 18% | -35% | $9,843,685 | -$227,250 | 3,248,741 | -2.3% | Melani Kenneth R. | 30 Jun 2025 |
| Raju Ajay | 3.7% | -78% | $893,750 | +$13,750 | 2,031,250 | +1.6% | Raju Ajay | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC | 5% | -49% | $2,835,244 | -$1,000,736 | 935,724 | -26% | Armistice Capital, LLC | 30 Jun 2025 |
| Hathaway John Jason | 4.5% | -33% | $2,426,885 | 800,952 | 0% | John Hathaway | 30 Jun 2025 |
As of 30 Jun 2026,
21
institutional investors reported holding
shares of
Medicus Pharma Ltd. - Common shares, no par value (MDCX).
This represents
2.9%
of the company’s total
outstanding shares.
2.62M
Full value: 2,620,743 · shares · 30 Jun 202691.69M
Full value: 91,685,830 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Headline period
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,400,982 | $386,909 | +$84,335 | $0.16 | 7 |
| 2026 Q2 | 2,620,743 | $1,179,646 | +$129,618 | $0.45 | 21 |
| 2026 Q1 | 2,319,481 | $6,483,722 | -$2,589,898 | $0.46 | 20 |
| 2025 Q4 | 3,939,093 | $6,026,447 | +$2,578,454 | $1.53 | 20 |
| 2025 Q3 | 2,119,467 | $4,905,211 | -$365,331 | $2.32 | 20 |
| 2025 Q2 | 2,206,052 | $6,595,875 | -$3,790,457 | $2.99 | 21 |
| 2025 Q1 | 3,051,629 | $11,352,061 | +$5,738,203 | $3.72 | 7 |
| 2024 Q4 | 1,503,368 | $3,741,062 | +$3,741,062 | $2.46 | 3 |